Clervonafusp alfa
- Generic Name
- Clervonafusp alfa
- Drug Type
- Biotech
- CAS Number
- 2145123-44-8
- Unique Ingredient Identifier
- I6M9Q08XBP
Intravenous VAL-1221 Lafora Expanded Access Protocol
- Conditions
- Lafora Disease
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- Parasail, LLC
- Registration Number
- NCT05930223
VAL-1221 Delivered Intravenously in Ambulatory and Ventilator-free Participants With Late-Onset Pompe Disease
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Valerion Therapeutics, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT02898753
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇬🇧National Hospital for Neurology and Neurosurgery, London, United Kingdom
🇺🇸University of California, Irvine, Orange, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath